Skip to main content
Premium Trial:

Request an Annual Quote

InDevR Gets FDA 510(k) Clearance for Influenza Assay

NEW YORK (GenomeWeb) — InDevR said today that it has received 510(k) clearance from the US Food and Drug Administration for its FluChip-8G Influenza A+B assay.

The RT-PCR-based in vitro diagnostic is designed to detect whole gene segments for influenza A and B viruses in order to identify and differentiate them. A machine learning algorithm then identifies the signal pattern of specific target virus groups to help characterize infections as seasonal or nonseasonal.

"This successful clearance follows several years of assay development with the goal of improving the nation's preparedness to respond to an influenza pandemic," InDevR Chief Technology Officer Erica Dawson said in a statement. "We hope that placement of this FluChip-8G technology in the field will bring us another step closer to ensuring timely detection of emerging influenza threats."

In 2014, Boulder, Colorado-based InDevR signed a $14.7 million contract with the Biomedical Advanced Research and Development Authority for the development of FluChip-8G.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.